04 February 2013 | News | By BioSpectrum Bureau
BGI-Shenzhen's subsidiary Beta Acquisition extends its cash tender offer to acquire Complete Genomics stocks until midnight of Wednesday, February 6, 2013
Singapore: BGI-Shenzhen (BGI) announced that its wholly-owned subsidiary Beta Acquisition, has extended its all cash tender offer to purchase all outstanding shares of common stock of Complete Genomics, at 12:00 midnight (New York City time) on Wednesday, February 6, 2013. The offer was previously scheduled to expire at 12:00 midnight (New York City time) on Friday, February 1, 2013.
Except for the extension of the offer expiration date, all other terms and conditions remain unchanged. The depositary for the offer has indicated that, as of the close of business on February 1, 2013, approximately 30.83 million shares or approximately 87 percent of common stock of Complete have been validly tendered in and not withdrawn from the offer, including shares of common stock of Complete subject to guaranteed delivery procedures.
BGI's financial advisor is Citi and its legal counsel is O'Melveny & Myers. Complete's financial adviser is Jefferies & Company and its legal counsel is Latham & Watkins.